France's prison population reaches record high
Over the past year, the number of people incarcerated grew by 6,000, taking the occupancy rate to 133.7 per cent.
France now has 83,681 inmates held in facilities that have a total capacity of just 62,570.
That figure is around 30 per cent worse than in England and Wales, where there are 88,000 prisoners and 89,000 places, figures last month showed.
The record overcrowding has seen 23 out of France's 186 detention facilities operating at more than twice their capacity, forcing some prisoners to sleep on mattresses on the floor.
The policy of fast-track justice in Emmanuel Macron's government, where prosecutors can bring a person to trial soon after being taken into custody, has been blamed for the situation.
These immediate hearings mean more people can be sentenced in a shorter amount of time, funnelling people into prison at a faster rate.
In 90 per cent of these cases, the outcome of these fast-track hearings is detention, whether pre-trial or to serve out a sentence, according to Dominique Simonnot, the head of a prison watchdog group in France.
France now sits behind Cyprus as the second worst country in the European Union for prison overcrowding, according to latest statistics.
Separate data published by Eurostat, the EU's statistical office, found that the highest overcrowding was observed in Cyprus, with an occupancy rate of 226.2, France at 122.9, and Italy at 119.1.
Justice Minister Gerald Darmanin, a hardline figure in Mr Macron's cabinet, unveiled proposals last month to house the country's most dangerous prisoners in French Guiana - an overseas territory situated north of Brazil - to try and accommodate the overflow.
Prison overcrowding is 'bad for absolutely everyone,' Mr Darmanin said in late April, citing the 'appalling conditions' for prisoners and 'the insecurity and violence' faced by prison officers.
That same month, 10 French prisons, from Paris to Marseille in the south, were hit by coordinated attacks in response to government attempts to tackle drug trafficking.
In the space of two days arsonists set fires to parked cars, many belonging to prison staff, outside jails in Villepinte, Nanterre, Aix-Luynes and Valence, while the entrance to one prison in Toulon was sprayed with more than a dozen bullets from an automatic weapon. No injuries were reported.
No group claimed responsibility for the attacks, but Le Parisien newspaper reported that vandalised cars were found tagged with the letters DDPF, which stands for Defending the Rights of French Prisoners.
A law currently going through the French parliament would also create a special prosecutor's office to deal with narcotics crimes and give new powers to investigators.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Oil jumps as Trump shortens Russia's deadline to end Ukraine war, US-EU trade deal spurs demand optimism
Oil prices jumped Monday as President Trump shortened a timeline for Russia to end the war with Ukraine, prompting concerns potential sanctions could hit supply. Meanwhile, an agreement between the US and EU on the framework of a trade deal spurred optimism over demand. West Texas Intermediate (CL=F) climbed 1.9% to trade above $66 per barrel, and Brent (BZ=F) crude, the international benchmark price, rose to nearly $69 per barrel. The trade deal between the European Union and the US announced on Sunday includes $750 billion in EU purchases of American oil and natural gas. The stocks of liquified natural gas producers like Cheniere Energy (LNG), NextDecade (NEXT), and Venture Global (VG) all rose Monday as well. The 15% tariff deal on US imports from the EU fueled investors optimism over an eventual agreement with China as Washington and Beijing launched renewed trade talks. Meanwhile on Monday, President Trump shortened a timeline on Russia to end the war with Ukraine, from 50 days to less than two weeks, spurring concerns of a supply shock ahead. The president has threatened 'secondary tariffs' on Russia and countries purchasing from Moscow. "If enforced, oil markets cannot ignore the impact of triple-digit tariffs on Russian oil, given the significant scale of Russian exports and limited OPEC spare capacity, potentially leading to a supply shock," JPMorgan's Natasha Kaneva and her team wrote in a note earlier this month. The EU recently approved tougher price caps on Russian crude exports expected to go into effect in early September as a way to curtail the country's revenue. JPMorgan analysts expect oil price volatility to increase heading into September, citing uncertainty around Russia. The analysts also noted increases in supply from the Organization of Petroleum Exporting Countries and its allies (OPEC+) will already have been absorbed into the market by the fall. Ines Ferre is a senior business reporter for Yahoo Finance. Follow her on Twitter at @ines_ferre. Click here for in-depth analysis of the latest stock market news and events moving stock prices. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
By Bhanvi Satija (Reuters) -The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said on Monday. The added costs could raise prices for consumers unless pharmaceutical companies take action to mitigate the impact of the tariffs, one of the analysts said. Pharmaceuticals had historically been exempt from duties. Medicines are the largest European exports to the United States by value and the EU accounts for about 60% of all pharmaceutical imports to the U.S. On Sunday, European officials said that a bilateral trade deal for an across-the-board 15% tariff included pharmaceuticals, except for some generic drugs, which would be subject to no tariffs. The U.S. has been conducting a national security investigation into the pharmaceutical sector and the industry has been bracing for separate sectoral tariffs. President Donald Trump said earlier this month, before negotiating the bilateral deal, that pharmaceutical tariffs could be as high as 200%. Some Wall Street analysts said that they do not expect additional tariffs on the EU as a result of the investigation, but others cautioned that the deal was not yet signed and that several questions remained unanswered. UBS analyst Matthew Weston said that he expects details of the trade deal to include protective measures for EU pharma exports from the U.S. investigation, especially since such measures are being discussed in negotiations with the United Kingdom and Switzerland. ING analyst Diederik Stadig also said that while tariffs on top of the 15% were not expected, even after the conclusion of the national security investigations, nothing is completely clear "until a trade deal is inked." Stadig estimates that these levies could add $13 billion to industry expenses without any mitigation strategies, and some of that could be ultimately borne by the consumer. Bernstein analyst Courtney Breen puts the additional expenses at $19 billion for the industry, but she notes that companies might be able to absorb some of the costs with the measures they have been implementing — such as stockpiling of drug products and new deals with contract researchers. Earlier this month, Sanofi said it will sell a manufacturing facility in New Jersey to Thermo Fisher, where the French drugmaker's therapies will continue to be manufactured. Roche's CEO Thomas Schinecker said last week that the company was increasing its U.S. inventories to avoid any immediate disruption from tariffs. UBS' Weston said that it was not immediately clear which generic drugs were exempted from duties under the deal, but any impact for generic drugmaker Sandoz for this year should mostly be manageable. Shares in pharmaceutical companies Sanofi, Roche and Sandoz Group all closed up between 0.5% and 1% on Monday.
Yahoo
12 minutes ago
- Yahoo
Germany's Merz says he did not expect better EU-US trade deal, German economy will suffer
BERLIN (Reuters) -German Chancellor Friedrich Merz said on Monday he was not satisfied with the result of trade talks with the United States, but "more simply wasn't achievable" and added the German economy would suffer "significant" damage due to the agreed tariffs. The trade deal announced on Sunday imposes a 15% import tariff on most EU goods - lower than the 30% once threatened by U.S. President Donald Trump but well above initial hopes of a zero-for-zero agreement. The rate almost halves the existing tariff rate on Europe's auto sector, a cornerstone of the German economy, from 27.5%, Merz pointed out. "But I am fully aware that the tariffs that remain — particularly the 15% versus 0% for imports into the EU — pose a serious burden for Germany's export-oriented economy," he told a press conference in Berlin. "I am not satisfied with this result in the sense of: 'This is good.' But I do say that, given the starting point we had with the United States, more simply wasn't achievable," he said. The German chancellor thanked the European Commission for its "tireless negotiations" with its U.S. counterparts, with involvement in particular of the German, French, and Italian governments. "I personally did not expect more than this result," he said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
